Molecular and immune biomarkers in acute respiratory distress syndrome a perspective from members of the pulmonary pathology society

Vera Luiza Capelozzi, Timothy Craig Allen, Mary Beth Beasley, Philip T. Cagle, Don Guinee, Lida P. Hariri, Aliya N. Husain, Deepali Jain, Sylvie Lantuejoul, Brandon Larsen, Ross Miller, Mari Mino-Kenudson, Mitra Mehrad, Kirtee Raparia, Anja Roden, Frank Schneider, Lynette M. Sholl, Maxwell Lawrence Smith

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Acute respiratory distress syndrome (ARDS) is a multifactorial syndrome with high morbidity and mortality rates, characterized by deficiency in gas exchange and lung mechanics that lead to hypoxemia, dyspnea, and respiratory failure. Histologically, ARDS is characterized by an acute, exudative phase, combining diffuse alveolar damage and noncardiogenic edema, followed by a later fibroproliferative phase. Despite an enhanced understanding of ARDS pathogenesis, the capacity to predict the development of ARDS and to risk-stratify patients with the disease remains limited. Biomarkers may help to identify patients at the greatest risk of developing ARDS, to evaluate response to therapy, to predict outcome, and to improve clinical trials. The ARDS pathogenesis is presented in this article, as well as concepts and information on biomarkers that are currently used clinically or are available for laboratory use by academic and practicing pathologists and the developing and validating of new assays, focusing on the assays' major biologic roles in lung injury and/or repair and to ultimately suggest innovative, therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)1719-1727
Number of pages9
JournalArchives of Pathology and Laboratory Medicine
Volume141
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Adult Respiratory Distress Syndrome
Biomarkers
Pathology
Lung
Lung Injury
Mechanics
Respiratory Insufficiency
Biological Assay
Dyspnea
Edema
Gases
Clinical Trials
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Molecular and immune biomarkers in acute respiratory distress syndrome a perspective from members of the pulmonary pathology society. / Capelozzi, Vera Luiza; Allen, Timothy Craig; Beasley, Mary Beth; Cagle, Philip T.; Guinee, Don; Hariri, Lida P.; Husain, Aliya N.; Jain, Deepali; Lantuejoul, Sylvie; Larsen, Brandon; Miller, Ross; Mino-Kenudson, Mari; Mehrad, Mitra; Raparia, Kirtee; Roden, Anja; Schneider, Frank; Sholl, Lynette M.; Smith, Maxwell Lawrence.

In: Archives of Pathology and Laboratory Medicine, Vol. 141, No. 12, 01.12.2017, p. 1719-1727.

Research output: Contribution to journalArticle

Capelozzi, VL, Allen, TC, Beasley, MB, Cagle, PT, Guinee, D, Hariri, LP, Husain, AN, Jain, D, Lantuejoul, S, Larsen, B, Miller, R, Mino-Kenudson, M, Mehrad, M, Raparia, K, Roden, A, Schneider, F, Sholl, LM & Smith, ML 2017, 'Molecular and immune biomarkers in acute respiratory distress syndrome a perspective from members of the pulmonary pathology society', Archives of Pathology and Laboratory Medicine, vol. 141, no. 12, pp. 1719-1727. https://doi.org/10.5858/arpa.2017-0115-SA
Capelozzi, Vera Luiza ; Allen, Timothy Craig ; Beasley, Mary Beth ; Cagle, Philip T. ; Guinee, Don ; Hariri, Lida P. ; Husain, Aliya N. ; Jain, Deepali ; Lantuejoul, Sylvie ; Larsen, Brandon ; Miller, Ross ; Mino-Kenudson, Mari ; Mehrad, Mitra ; Raparia, Kirtee ; Roden, Anja ; Schneider, Frank ; Sholl, Lynette M. ; Smith, Maxwell Lawrence. / Molecular and immune biomarkers in acute respiratory distress syndrome a perspective from members of the pulmonary pathology society. In: Archives of Pathology and Laboratory Medicine. 2017 ; Vol. 141, No. 12. pp. 1719-1727.
@article{ade298869c5e48a980161973b9dc048f,
title = "Molecular and immune biomarkers in acute respiratory distress syndrome a perspective from members of the pulmonary pathology society",
abstract = "Acute respiratory distress syndrome (ARDS) is a multifactorial syndrome with high morbidity and mortality rates, characterized by deficiency in gas exchange and lung mechanics that lead to hypoxemia, dyspnea, and respiratory failure. Histologically, ARDS is characterized by an acute, exudative phase, combining diffuse alveolar damage and noncardiogenic edema, followed by a later fibroproliferative phase. Despite an enhanced understanding of ARDS pathogenesis, the capacity to predict the development of ARDS and to risk-stratify patients with the disease remains limited. Biomarkers may help to identify patients at the greatest risk of developing ARDS, to evaluate response to therapy, to predict outcome, and to improve clinical trials. The ARDS pathogenesis is presented in this article, as well as concepts and information on biomarkers that are currently used clinically or are available for laboratory use by academic and practicing pathologists and the developing and validating of new assays, focusing on the assays' major biologic roles in lung injury and/or repair and to ultimately suggest innovative, therapeutic approaches.",
author = "Capelozzi, {Vera Luiza} and Allen, {Timothy Craig} and Beasley, {Mary Beth} and Cagle, {Philip T.} and Don Guinee and Hariri, {Lida P.} and Husain, {Aliya N.} and Deepali Jain and Sylvie Lantuejoul and Brandon Larsen and Ross Miller and Mari Mino-Kenudson and Mitra Mehrad and Kirtee Raparia and Anja Roden and Frank Schneider and Sholl, {Lynette M.} and Smith, {Maxwell Lawrence}",
year = "2017",
month = "12",
day = "1",
doi = "10.5858/arpa.2017-0115-SA",
language = "English (US)",
volume = "141",
pages = "1719--1727",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "12",

}

TY - JOUR

T1 - Molecular and immune biomarkers in acute respiratory distress syndrome a perspective from members of the pulmonary pathology society

AU - Capelozzi, Vera Luiza

AU - Allen, Timothy Craig

AU - Beasley, Mary Beth

AU - Cagle, Philip T.

AU - Guinee, Don

AU - Hariri, Lida P.

AU - Husain, Aliya N.

AU - Jain, Deepali

AU - Lantuejoul, Sylvie

AU - Larsen, Brandon

AU - Miller, Ross

AU - Mino-Kenudson, Mari

AU - Mehrad, Mitra

AU - Raparia, Kirtee

AU - Roden, Anja

AU - Schneider, Frank

AU - Sholl, Lynette M.

AU - Smith, Maxwell Lawrence

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Acute respiratory distress syndrome (ARDS) is a multifactorial syndrome with high morbidity and mortality rates, characterized by deficiency in gas exchange and lung mechanics that lead to hypoxemia, dyspnea, and respiratory failure. Histologically, ARDS is characterized by an acute, exudative phase, combining diffuse alveolar damage and noncardiogenic edema, followed by a later fibroproliferative phase. Despite an enhanced understanding of ARDS pathogenesis, the capacity to predict the development of ARDS and to risk-stratify patients with the disease remains limited. Biomarkers may help to identify patients at the greatest risk of developing ARDS, to evaluate response to therapy, to predict outcome, and to improve clinical trials. The ARDS pathogenesis is presented in this article, as well as concepts and information on biomarkers that are currently used clinically or are available for laboratory use by academic and practicing pathologists and the developing and validating of new assays, focusing on the assays' major biologic roles in lung injury and/or repair and to ultimately suggest innovative, therapeutic approaches.

AB - Acute respiratory distress syndrome (ARDS) is a multifactorial syndrome with high morbidity and mortality rates, characterized by deficiency in gas exchange and lung mechanics that lead to hypoxemia, dyspnea, and respiratory failure. Histologically, ARDS is characterized by an acute, exudative phase, combining diffuse alveolar damage and noncardiogenic edema, followed by a later fibroproliferative phase. Despite an enhanced understanding of ARDS pathogenesis, the capacity to predict the development of ARDS and to risk-stratify patients with the disease remains limited. Biomarkers may help to identify patients at the greatest risk of developing ARDS, to evaluate response to therapy, to predict outcome, and to improve clinical trials. The ARDS pathogenesis is presented in this article, as well as concepts and information on biomarkers that are currently used clinically or are available for laboratory use by academic and practicing pathologists and the developing and validating of new assays, focusing on the assays' major biologic roles in lung injury and/or repair and to ultimately suggest innovative, therapeutic approaches.

UR - http://www.scopus.com/inward/record.url?scp=85037058535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037058535&partnerID=8YFLogxK

U2 - 10.5858/arpa.2017-0115-SA

DO - 10.5858/arpa.2017-0115-SA

M3 - Article

VL - 141

SP - 1719

EP - 1727

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 12

ER -